AlphAIAlphAI — Financial news for AI agents
thepharmaletter.comSEP 292 min read$TEVA

FDA nod for Teva’s Degevma biosimilar

Teva Pharmaceutical Industries (TEVA) received FDA approval for Degevma, a biosimilar to Amgen's Xgeva (denosumab). Degevma is indicated for preventing bone complications in advanced cancer, treating giant cell tumors, and managing hypercalcemia of malignancy. This approval expands Teva's oncology portfolio.

Original reporting
thepharmaletter.com
Published Sep 29, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
FDA nod for Teva’s Degevma biosimilar — source image
Source · thepharmaletter.com
Decision brief

The 30-second read

$TEVABullishHigh
01

Why it matters

The approval expands Teva's oncology portfolio and may capture market share from Amgen's Xgeva.

02

Market read

Regulatory clearance for a new biosimilar is a material catalyst for Teva's stock.

03

What to watch

Manufacturing scale and market uptake timeline could delay revenue.

Relevance 9/10Novelty 9/10Timing: today

Background

Teva announced the FDA approval of Degevma, a denosumab biosimilar for bone complications and related indications.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

FDA approved Teva's Degevma biosimilar to Xgeva, a new product launch.

Expected impact

likely upward pressure as investors price in the approval.

Evidence & confidence

FDA approval removes regulatory uncertainty and opens revenue potential.

Market effects

Sector

May boost the broader biosimilar and oncology drug sector.

Regional

Positive for US and Israeli pharma markets.

Global

Adds to global competition in denosumab therapies.

Counterpoint

What could challenge this read

Potential pricing pressure if payer reimbursement is limited.

Key entities

  • company
    Teva Pharmaceutical Industries

    US-listed pharmaceutical company receiving FDA approval.

  • product
    Xgeva

    Amgen's original denosumab therapy.

Read at source← All news

Also covered by

6 outlets

Related articles

SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

biopharminternational.com2 min
SEP 30
$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

onclive.com2 min
SEP 29
$TEVAHighAI 9/10

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Teva Pharmaceutical Industries received U.S. FDA approval for denosumab-adet, a biosimilar to denosumab, for all indications of the reference product. The approval expands Teva's biosimilar portfolio in oncology and bone health, offering a new treatment option. Denosumab-adet is approved for preventing skeletal-related events in advanced cancer, treating giant cell tumor of bone, and managing hypercalcemia of malignancy.

oncodaily.com2 min
SEP 29
$TEVAMedAI 8/10

Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva

Teva Pharmaceutical (TEVA) received FDA approval for DEGEVMA, a biosimilar to Xgeva. The approval is based on data showing comparable efficacy, safety, and immunogenicity. DEGEVMA is indicated for bone complications in cancer patients and other conditions. Teva plans to launch DEGEVMA and PONLIMSI in the U.S. soon. TEVA stock closed at $38.88, up 0.31% in after-hours trading.

rttnews.com1 min